Anastasia-Stefania Alexopoulos
Overview
Explore the profile of Anastasia-Stefania Alexopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munshi M, Kahkoska A, Neumiller J, Alexopoulos A, Allen N, Cukierman-Yaffe T, et al.
Lancet Diabetes Endocrinol
. 2025 Feb;
PMID: 39978368
Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ability to perform self-care. Most diabetes guidelines focus on improving glycaemia through addition...
2.
Boggan J, Sankineni S, Dennis P, Chen D, Sledge T, Halpern D, et al.
Ann Intern Med
. 2025 Jan;
178(2):229-240.
PMID: 39805113
Background: Postdischarge contacts (PDCs) after hospitalization are common practice, but their effectiveness in reducing use of acute care after discharge remains unclear. Purpose: To assess the effects of PDC on...
3.
Miller K, Geyer B, Alexopoulos A, Moylan C, Pagidipati N
Dig Dis Sci
. 2024 Nov;
70(1):154-167.
PMID: 39560808
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a leading cause of morbidity and mortality, and health disparities have been shown to...
4.
Alexopoulos A, Danus S, Parish A, Olsen M, Batch B, Thacker C, et al.
Diabetes Ther
. 2024 Sep;
15(11):2417-2427.
PMID: 39276291
Introduction: Patients with type 2 diabetes (T2D), particularly those from historically marginalized racial and ethnic groups, are at high risk of poor outcomes from metabolic dysfunction-associated steatotic liver disease (MASLD)....
5.
Alexopoulos A, Parish A, Olsen M, Batch B, Moylan C, Crowley M
Endocr Pract
. 2024 May;
30(7):663-669.
PMID: 38697305
Objective: To assess frequency of evidence-based management (EBM) of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes (T2D), and to examine for racial/ethnic disparities in the...
6.
Duffy R, Jeffreys A, Coffman C, Alexopoulos A, Tarkington P, Bosworth H, et al.
Telemed J E Health
. 2024 Feb;
30(6):e1790-e1797.
PMID: 38377570
7.
Alexopoulos A, Parish A, Olsen M, Batch B, Moylan C, Crowley M
BMJ Open Diabetes Res Care
. 2023 Nov;
11(6).
PMID: 38030391
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) is highly prevalent in type 2 diabetes (T2D). Pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1RA) are medications used in T2D that can resolve MASH and...
8.
Alexopoulos A, Crowley M, Kahkoska A
Diabetes Care
. 2023 May;
46(6):1137-1139.
PMID: 37220268
No abstract available.
9.
Zupa M, Alexopoulos A, Esteve L, Rosland A
J Endocr Soc
. 2023 Apr;
7(5):bvad039.
PMID: 37035500
Background: Recent recommendations guiding appropriate use of telemedicine for endocrinology care have largely relied on expert opinion due to limited evidence on factors that increase quality of telemedicine care. In...
10.
Alexopoulos A, Soliman D, Lewinski A, Strawbridge E, Steinhauser K, Edelman D, et al.
J Diabetes Complications
. 2022 Dec;
37(1):108364.
PMID: 36525906
In this single-arm pilot study, we demonstrated feasibility and acceptability of an insulin simplification intervention in patients with persistent, poorly-controlled type 2 diabetes on complex insulin regimens. While not powered...